CAR-T cells represent the most effective therapy for blood cancer patients with remarkable rates of complete remission, even in patients who otherwise only had months to live. However, current CAR-T products are manufactured by complex and expensive technologies not suitable to address market and patient’s needs. T-CURX proprietary technologies (already validated in Phase I clinical trials) will overcome the current limitations to CAR-T cell therapies, lowering complexities and costs in manufacturing, thereby giving many more patients with both hematological malignancies and solid tumors access to these promising personalized medicines. Our scalable therapies enable more patients to have a chance to achieve complete and long-term remission. With our experienced team and innovative technologies, we aim at reducing high costs and complex manufacturing, expanding the limited spectrum of indications and focusing on additional target molecules and ultimately at establishing our technology as the gold-standard in CAR-T cell therapies.